Acting FDA Chief Janet Woodcock ruled out as permanent nominee - Bloomberg News
Reuters
Published Aug 19, 2021 06:31PM ET
Updated Aug 19, 2021 07:10PM ET
(Reuters) -U.S. President Joe Biden's administration has ruled out nominating Janet Woodcock as the permanent head of the Food and Drug Administration (FDA), Bloomberg News reported https://bloom.bg/2WdjOqJ on Thursday, citing people familiar with the matter.
Woodcock, who has served as acting commissioner since Biden took office, has faced firm opposition on Capitol Hill for the job from lawmakers including Democrat Senator Joe Manchin, a key swing vote in the evenly divided chamber, the report said.
Manchin had criticized the agency over the controversial accelerated approval this year of Biogen Inc (NASDAQ:BIIB)'s Alzheimer's drug, Aduhelm, according to the report.
When contacted for comment, an FDA spokesperson referred questions to the White House.
A White House official said no one had been ruled in or out until the nomination was announced.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.